# HM2024-11: A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) VERSUS POLATUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA

**Status:** Recruiting

## Eligibility Criteria

**Sex:** Male or Female
**Age Group:** 18 years and over
This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- 18 to 80 years old - have not received any treatment for Large B-Cell Lymphoma - able to walk and do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

**Exclusion Criteria:**

- prior solid organ transplantation - history of significant cardiovascular disease - current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease - clinically significant liver disease - chronic hepatitis B infection, hepatitis C, or HIV

## Conditions & Interventions

**Conditions:**
Cancer
**Keywords:**
Clinics and Surgery Center (CSC), Large B-Cell Lymphoma, LBCL, lymphoma

## More Information

**Description:** The purpose of this study is to compare the efficacy and safety of glofitamab, a novel cluster of differentiation (CD) 20/CD3 bispecific antibody, in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus Pola-R-CHP in patients with previously untreated CD20-positive large B-cell lymphoma (LBCL).
**Study Contact:** Sanjal Desai - desai171@umn.edu
**Principal Investigator:** Sanjal Desai
**Phase:** PHASE3
**IRB Number:** STUDY00022042